SCHEMBL20162153

SCHEMBL20162153

CCOC(=O)c1cnc2c(c1)CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.47
ESR2 Q92731 1/20 0.46
NR1H2 P55055 1/20 0.46
MAPT P10636 3/20 0.44
ATM Q13315 1/20 0.42
POLB P06746 2/20 0.39
GPR119 Q8TDV5 2/20 0.39
TP53 P04637 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
P2RY12 Q9H244 2/20 0.38
TRPV1 Q8NER1 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18379843 0.90 ATM (0.42) ADORA1ESR2NR1H2MAPTATM
SCHEMBL31013919 0.90 ATM (0.42) ADORA1ESR2NR1H2MAPTATM
SCHEMBL722429 0.88 ESR2 (0.49) ESR2NR1H2MAPTGPR119
SCHEMBL29042343 0.85 ESR2 (0.51) ADORA1ESR2NR1H2MAPTGPR119
SCHEMBL20364359 0.84 ESR2 (0.50) ADORA1ESR2NR1H2MAPTGPR119
SCHEMBL20162166 0.83 ESR2 (0.49) ADORA1ESR2NR1H2MAPTGPR119
SCHEMBL1017184 0.83 KDM4E (0.41) MAPTATMALDH1A1MEN1KMT2A
SCHEMBL2077127 0.83 RAB9A (0.46) MAPTPOLBALDH1A1GAAMEN1
SCHEMBL25347509 0.82 NAMPT (0.43) MAPTATMGPR119NPSR1
SCHEMBL721062 0.82 ESR2 (0.48) ESR2NR1H2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10294237-B2 Bicyclic heterocyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-05-21 US disclosed
US-10294237-B2 Bicyclic heterocyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-05-21 US disclosed
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed
EP-3323809-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2018-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294237-B2 Bicyclic heterocyclic amide derivative NR0B1, NR2E1, NR0B2 ADORA1 724/4885ESR2 620/4885NR1H2 313/4885
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE NR0B1, NR2E1, NR0B2 ADORA1 724/4885ESR2 620/4885NR1H2 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.